Introduction
Perhexiline has been previously shown to be effective in the treatment of angina pectoris due to coronary artery disease (Burns-Cox et al., 1971; Hoekenga et al., 1973) . The mode of action is not fully understood but haemodynamic studies in man suggest that exercise-induced ischaemia is reduced by allowing better oxygen extraction by the myocardium and by reduction of heart rate on exercise (Pepine, Schang and Bemiller, 1973; Morgans and Rees, 1973) . Heart rate is not reduced at rest when taking perhexilene, as it is when taking n-blockers.
This study compared the efficacy of perhexiline against that of the n-blocking agent, oxprenolol, in patients with angina pectoris. It was undertaken in a single-blind random fashion.
Methods
Criteria for admission to the trial were as follows: 1. Informed consent to be obtained. 2. Patients of either sex to be aged less than 70 years and have typical exercise/emotion-induced angina pectoris (relieved by glyceryl trinitrate (GTN)) due to coronary artery disease, as proved by: (a) ischaemic type ST or T wave changes by ECG; or (b) a past documented myocardial infarction; or (c) coronary arteriographic evidence of stenosis in excess of 70%*.
3. Angina pectoris to have been stable in frequency over the past 3 months with attacks averaging four or more per week on no treatment other than GTN.
Patients experiencing a myocardial infarction less than three months previously were excluded, as were those with uncontrolled heart failure, diabetes, bronchospastic disease, renal or hepatic dysfunction, sinus bradycardia of s 50 beats/min, conduction defects other than first degree or unifascicular block and any concomitant disease whose treatment was likely to influence the conduct of the trial. Systemic hypertension was not a contra-indication to the trial (five patients being so affected BP >160/90 mmHg) and other treatments, e.g. diuretics, lipidlowering agents, were not withdrawn.
On admission to the trial each patient was given a diary card on which to enter every day the number and severity of anginal attacks and the number of GTN tablets consumed (patients being told only to take GTN to relieve pain and not for prophylactic purposes). Patients were then seen every 2 weeks throughout the trial.
The first 4 weeks consisted of observation only to ascertain that the required anginal frequency was being met without treatment other than GTN. At the end of this period oxprenolol or perhexiline was introduced to the treatment in a random fashion, the patient not being told which drug he would receive. Over the next 6-8 weeks the dosage of each drug was then built up from the starting doses of perhexiline 100 mg twice/day and oxprenolol 40 mg thrice/day, either to the maximally effective ( Table 1 also shows effects of the drugs on heart rate, blood pressure and on weight. Heart rate and both systolic and diastolic pressures were reduced by oxprenolol (P<002). No significant difference was noted on perhexiline. There was a tendency to lose weight on perhexiline and to gain weight on oxprenolol (P<0-02), the maximum weight-loss being 6-6 kg on perhexiline and the maximum gain 4 0 kg on oxprenolol. Transarhinase elevation was seen in four patients on perhexiline to a maximum SGPT of 176 (hospital normal 40). One patient on oxprenolol had an SGOT of 47. All these abnormal transaminases settled to normal after a change of drug. There were no significant resting ECG changes on either drug.
Six patients were withdrawn from the trial. There were two deaths from coronary thrombosis (one on each drug and both during the first period of treatment). One patient, who had previously Table 2 for the fifteen patients who completed both drug regimes; six patients had no side effects to either drug, while seven patients had side effects to both. Although most side effects were of short duration, in five patients they were sufficient to cause dose limitation (perhexiline x 5; oxprenolol x 2). One patient developed peripheral neuropathy on perhexiline some 6 months after completion of the trial.
All patients thought both drugs had helped their angina. When asked to express preference, twelve chose perhexiline and two oxprenolol.
Discussion
After any new drug has been established as being markedly better than placebo in the treatment of a disease it is logical to test that drug against known effective therapy. This has been done for oxprenolol against other 5-blocking agents (e.g. Sharma et al., 1971) . It is as effective in angina pectoris as other drugs of its class. Perhexiline has been previously tested against both placebo and the 5-blocking drugs propranolol and practolol (Armstrong et al., 1974) .
Whilst both drugs were markedly better than placebo, as in this study, perhexiline was also significantly more effective than the 5-blockers. However, a possible criticism of that trial relates to the doses of propranolol and practolol used.
It is now a notorious fact that the common reason Hypoglycaemia as a result of perhexiline has been reported (Roger et al., 1975) but there were no symptoms suggestive of this in this study. Severe weight-loss seems a more definite side effect (Grand and Sepulcre, 1974) and it is interesting that there was a significant difference in weight-change between perhexiline and oxprenolol in this study, the maximum loss being 6-6 kg with perhexiline over 1 iweeks. (1977) or due to axonal toxicity as yet remains uncertain. It appears to be mainly confined to 'slow' metabolizers of the drug (Singlas, 1977) who form a minority (15-20%4) of the population, at least as studied in the U.S.A. (Wright, 1976) . Peripheral neuropathy usually occurs after long-term administration as it did in one patient from this study some months after completion of the trial and in two other patients not part of the trial -all confirmed by electromyography. Repeat electromyograms some 6 to 12 months after cessation of the drug were normal in two cases and much improved in the third, these findings being in keeping with the clinical assessment. Such improvement in peripheral neuropathy after cessation of the drug is similar to that found in all studied cases to date.
The main other neurological complication after long-term administration of perhexiline is papilloedema, often in association with peripheral neuropathy (Bousser et al., 1976; Bousser et al., 1977) , and occasionally with loss of visual acuity and ataxia (Stephens et al., 1978) . Whether this papilloedema represents a true rise in intracranial pressure is still being discussed but, like peripheral neuropathy, it too resolves on cessation of the drug. Other reports of neurological complications to the drug include dysarthria and deafness (Epstein 1977 It is unfortunate that perhexiline should have side effects that make it in many ways unsuitable for administration in general practice. It is a most effective treatment of angina pectoris. This study and that of Armstrong et al. (1974) suggest it to be more effective than 5-blockers. Other advantages are its lack of effect on bronchial muscle or respiratory function (Sharma et al., 1973) , and its mild diuretic effect (Czerwinski et al., 1973) , its anti-arrhythmic properties (Drake et al., 1973) , and its lack of any myocardial depressant action (Pepine et al., 1973) . However, despite all these advantages, it does not seem a drug best suited for first choice treatment of angina pectoris.
Nevertheless, whilst failure of response to conventional 5-blocking therapy in angina pectoris should lead to consideration of surgery, many patients exist whose disease is not amenable to surgery. Perhexiline should be considered in these patients. It is a personal impression that resistant angina responds better to the use of perhexiline and a 5-blocking drug concurrently than to either drug individually. This could be expected in view of their differing modes of action but no definite data exist. Finally, perhexiline seems a logical drug for use in patients with bronchospasm or heart failure. For these special categories of patients the potential benefit obtainable would seem to outweigh the added risk of its side effects. 
